1. 1319PPost-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO). (23rd October 2018) Authors: Pusceddu, S; Vernieri, C; Di Maio, M; Prinzi, N; Torchio, M; Buzzoni, R; Truong-Thanh, X-M; Mazzaferro, V; de Braud, F G M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1324PThe role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs). (23rd October 2018) Authors: Prinzi, N; Seregni, E; Raimondi, A; Maccauro, M; Corti, F; Lo Russo, G; Nichetti, F; Torchio, M; Coppa, J; Peverelli, G; Pagani, F; Di Bartolomeo, M; Mazzaferro, V; de Braud, F; Pusceddu, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗